MYLAN INC., as Issuer, SOMERSET PHARMACEUTICALS, INC., as Guaranteeing Subsidiary, The GUARANTORS from time to time parties hereto and THE BANK OF NEW YORK MELLON, as Trustee FIRST SUPPLEMENTAL INDENTURE DATED as of NOVEMBER 29, 2011 TO THE INDENTURE...
Exhibit 4.2
as Issuer,
SOMERSET PHARMACEUTICALS, INC.,
as Guaranteeing Subsidiary,
The GUARANTORS from time to time parties hereto
and
THE BANK OF NEW YORK MELLON,
as Trustee
DATED as of NOVEMBER 29, 2011
TO THE INDENTURE
DATED as of MAY 19, 2010,
7.625% SENIOR NOTES DUE 2017
7.875% SENIOR NOTES DUE 2020
First Supplemental Indenture (this “First Supplemental Indenture”), dated as of November 29, 2011, among Mylan Inc., a Pennsylvania corporation (the “Company”), Somerset Pharmaceuticals, Inc. (the “Guaranteeing Subsidiary”), a Delaware corporation and a Subsidiary of the Company, the other Subsidiary Guarantors (as defined in the Indenture referred to herein) and The Bank of New York Mellon, as trustee under the Indenture referred to below (the “Trustee”).
W I T N E S S E T H
WHEREAS, the Company has heretofore executed and delivered to the Trustee an indenture (the “Indenture”), dated as of May 19, 2010, providing for the issuance of 7.625% Senior Notes due 2017 and 7.875% Senior Notes due 2020 (together, the “Notes”);
WHEREAS, the Indenture provides that under certain circumstances the Guaranteeing Subsidiary shall execute and deliver to the Trustee a supplemental indenture pursuant to which the Guaranteeing Subsidiary shall unconditionally guarantee all of the Company’s Obligations under the Notes and the Indenture on the terms and conditions set forth herein (the “Note Guarantee”); and
WHEREAS, pursuant to Section 8.01 of the Indenture, the parties hereto are authorized to execute and deliver this First Supplemental Indenture.
NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the parties hereto mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows:
1. Capitalized Terms. Capitalized terms used herein without definition shall have the meanings assigned to them in the Indenture.
2. Agreement to Guarantee. The Guaranteeing Subsidiary hereby agrees to provide an unconditional Guarantee on the terms and subject to the conditions set forth in the Guarantee and in the Indenture including but not limited to Article 10 thereof.
3. No Recourse Against Others. No director, officer, employee or stockholder of the Company or the Guaranteeing Subsidiary will have any liability for any of the Company’s or the Guaranteeing Subsidiary’s obligations under the Notes, the Indenture, the Note Guarantees or for any claim based on, in respect of, or by reason of, such obligations or their creation. Each Holder of Notes by accepting a Note waives and releases all such liability. The waiver and release are part of the consideration for issuance of the Notes and the Note Guarantee.
4. NEW YORK LAW TO GOVERN. THE INTERNAL LAW OF THE STATE OF NEW YORK WILL GOVERN AND BE USED TO CONSTRUE THIS SUPPLEMENTAL INDENTURE WITHOUT GIVING EFFECT TO APPLICABLE PRINCIPLES OF CONFLICTS OF LAW TO THE EXTENT THAT THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION WOULD BE REQUIRED THEREBY.
5. Counterparts. The parties may sign any number of copies of this First Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement.
6. Effect of Headings. The Section headings herein are for convenience only and shall not affect the construction hereof.
7. The Trustee. The Trustee shall not be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this First Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Guaranteeing Subsidiary and by the Company.
2
IN WITNESS WHEREOF, the parties hereto have caused this First Supplemental Indenture to be duly executed and attested, all as of the date first above written.
Dated: November 29, 2011,
| SOMERSET PHARMACEUTICALS, INC. | ||
| By: | ||
| Name: Xxxxxxx Xxxxxxx | ||
| Title: Secretary | ||
| MYLAN INC. | ||
| By: | ||
| Name: | Xxxx X. Xxxxxxx | |
| Title: | Executive Vice President and Chief Financial Officer | |
| XXX, INC. | ||
| By: | ||
| Name: Xxxxxxx Xxxxxxx | ||
| Title: Secretary | ||
| XXX PHARMA, L.P., by Xxx, Inc., its general partner | ||
| By: | ||
| Name: Xxxxxxx Xxxxxxx | ||
| Title: Secretary | ||
Signature Page to May 2010 Supplemental Indenture
| XXX LIMITED PARTNER, INC. | ||
| By: | ||
| Name: Xxxxxxx Xxxxxxx | ||
| Title: Secretary | ||
| EMD, INC. | ||
| By: | ||
| Name: Xxxxxxx Xxxxxxx | ||
| Title: Secretary | ||
| MLRE LLC | ||
| By: | ||
| Name: Xxxxxxx Xxxxxxx | ||
| Title: Manager | ||
| MP AIR, INC. | ||
| By: | ||
| Name: Xxxxxxx Xxxxxxx | ||
| Title: Secretary | ||
| MYLAN BERTEK PHARMACEUTICALS INC. | ||
| By: | ||
| Name: Xxxxxxx Xxxxxxx | ||
| Title: Secretary | ||
| MYLAN CARIBE, INC. | ||
| By: | ||
| Name: Xxxxxxx Xxxxxxx | ||
| Title: Secretary | ||
Signature Page to May 2010 Supplemental Indenture
| MYLAN DELAWARE INC. | ||
| By: | ||
| Name: Xxxxxxx Xxxxxxx | ||
| Title: Secretary | ||
| MYLAN INSTITUTIONAL INC. (formerly known as UDL Laboratories, Inc.) | ||
| By: | ||
| Name: Xxxxxxx Xxxxxxx | ||
| Title: Secretary | ||
| MYLAN LLC | ||
| By: | ||
| Name: Xxxxxxx Xxxxxxx | ||
| Title: Manager | ||
| MYLAN LHC INC. | ||
| By: | ||
| Name: Xxxxxxx Xxxxxxx | ||
| Title: Secretary | ||
| MYLAN PHARMACEUTICALS INC. | ||
| By: | ||
| Name: Xxxxxxx Xxxxxxx | ||
| Title: Secretary | ||
| MYLAN TECHNOLOGIES, INC. | ||
| By: | ||
| Name: Xxxxxxx Xxxxxxx | ||
| Title: Secretary | ||
Signature Page to May 2010 Supplemental Indenture
| THE BANK OF NEW YORK MELLON, as Trustee | ||
| By: | ||
| Authorized Signatory | ||
Signature Page to May 2010 Supplemental Indenture
